321 related articles for article (PubMed ID: 23533246)
1. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
[TBL] [Abstract][Full Text] [Related]
2. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
[TBL] [Abstract][Full Text] [Related]
3. Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome.
Buffet A; Smati S; Mansuy L; Ménara M; Lebras M; Heymann MF; Simian C; Favier J; Murat A; Cariou B; Gimenez-Roqueplo AP
J Clin Endocrinol Metab; 2014 Feb; 99(2):E369-73. PubMed ID: 24276449
[TBL] [Abstract][Full Text] [Related]
4. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
[TBL] [Abstract][Full Text] [Related]
5. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
[TBL] [Abstract][Full Text] [Related]
6. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
[TBL] [Abstract][Full Text] [Related]
7. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
[TBL] [Abstract][Full Text] [Related]
8. Identification of Novel Mutations and Expressions of
Islam F; Pillai S; Gopalan V; Lam AK
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33114456
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.
Gaal J; Burnichon N; Korpershoek E; Roncelin I; Bertherat J; Plouin PF; de Krijger RR; Gimenez-Roqueplo AP; Dinjens WN
J Clin Endocrinol Metab; 2010 Mar; 95(3):1274-8. PubMed ID: 19915015
[TBL] [Abstract][Full Text] [Related]
10. HIF2 and endocrine neoplasia: an evolving story.
Maher ER
Endocr Relat Cancer; 2013 Jun; 20(3):C5-7. PubMed ID: 23653463
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
12. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.
Yao L; Schiavi F; Cascon A; Qin Y; Inglada-Pérez L; King EE; Toledo RA; Ercolino T; Rapizzi E; Ricketts CJ; Mori L; Giacchè M; Mendola A; Taschin E; Boaretto F; Loli P; Iacobone M; Rossi GP; Biondi B; Lima-Junior JV; Kater CE; Bex M; Vikkula M; Grossman AB; Gruber SB; Barontini M; Persu A; Castellano M; Toledo SP; Maher ER; Mannelli M; Opocher G; Robledo M; Dahia PL
JAMA; 2010 Dec; 304(23):2611-9. PubMed ID: 21156949
[TBL] [Abstract][Full Text] [Related]
13. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.
Remacha L; Pirman D; Mahoney CE; Coloma J; Calsina B; Currás-Freixes M; Letón R; Torres-Pérez R; Richter S; Pita G; Herráez B; Cianchetta G; Honrado E; Maestre L; Urioste M; Aller J; García-Uriarte Ó; Gálvez MÁ; Luque RM; Lahera M; Moreno-Rengel C; Eisenhofer G; Montero-Conde C; Rodríguez-Antona C; Llorca Ó; Smolen GA; Robledo M; Cascón A
Am J Hum Genet; 2019 Apr; 104(4):651-664. PubMed ID: 30929736
[TBL] [Abstract][Full Text] [Related]
15. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
16. Human pheochromocytomas show reduced p27Kip1 expression that is not associated with somatic gene mutations and rarely with deletions.
Pellegata NS; Quintanilla-Martinez L; Keller G; Liyanarachchi S; Höfler H; Atkinson MJ; Fend F
Virchows Arch; 2007 Jul; 451(1):37-46. PubMed ID: 17554557
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster.
Fliedner SM; Shankavaram U; Marzouca G; Elkahloun A; Jochmanova I; Daerr R; Linehan WM; Timmers H; Tischler AS; Papaspyrou K; Brieger J; de Krijger R; Breza J; Eisenhofer G; Zhuang Z; Lehnert H; Pacak K
Neoplasia; 2016 Sep; 18(9):567-76. PubMed ID: 27659016
[TBL] [Abstract][Full Text] [Related]
18. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.
Taïeb D; Yang C; Delenne B; Zhuang Z; Barlier A; Sebag F; Pacak K
J Clin Endocrinol Metab; 2013 May; 98(5):E908-13. PubMed ID: 23539726
[TBL] [Abstract][Full Text] [Related]
19. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
[TBL] [Abstract][Full Text] [Related]
20. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
